Lapatinib antagonizes multidrug resistance-associated protein 1 mediated multidrug resistance by inh

• 作 者: Shao-linMa;Ya-pengHu;FangWang;Zhen-congHuang;Yi-fanChen;Xiao-kunWang;Li-wuFu;
• 机 构: Collaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,
• 出 处: 2014医学科学前沿暨第三届个体化治疗与抗肿瘤药物研究新趋向研讨会
• 发表日期: 2014年期

　　Lapatinib, a tyrosine kinase inhibitor (TKI), is used in the treatment of advanced or metastatic breast cancer overexpressing human epidermal receptor 2 (HER2).Lapatinib can modulate the function of ATP-binding cassette (ABC) transporters (ABCB1 and ABCG2) which are the major mechanism responsible for multidrug resistance (MDR) in cancer.In this study, we investigated the effect of lapatinib on multidrug resistance-associated protein 1(MRP1/ABCC1), MRP2 (ABCC2), MRP4 (ABCC4) and lung relative resistance protein (LRP) drug efflux pump.